Physician profile
Leonard Ellison
NPI 1679575328
$9,094.20
in general payments reported to CMS, 2019-2025
47 companies · $2,024 in 2025
The $2,024 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $819 · 2020: $728 · 2021: $1,022 · 2022: $1,245 · 2023: $1,750 · 2024: $1,506 · 2025: $2,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,084 · Education: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,083.75 |
| Education | $196.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $1,203.16 | 2019-2022 | |
| Ucb, INC. | $837.94 | 2019-2025 | Fintepla, Nayzilam, Briviact |
| Jazz Pharmaceuticals INC. | $519.26 | 2025 | |
| Sumitomo Pharma America, INC. | $518.06 | 2023-2025 | Aptiom, Gemtesa |
| Teva Pharmaceuticals USA, INC. | $516.02 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Astrazeneca Pharmaceuticals LP | $512.72 | 2019-2025 | Farxiga, Lokelma, Airsupra |
| Kestra Medical Technology Services, INC. | $426.30 | 2022-2024 | Assure Wcd |
| Otsuka America Pharmaceutical, INC. | $371.19 | 2023-2024 | Rexulti, Nuedexta |
| Neurelis, INC. | $276.77 | 2023-2025 | Valtoco |
| Glaxosmithkline, LLC. | $269.67 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $265.07 | 2019-2023 | |
| Astellas Pharma US INC | $262.12 | 2019-2025 | Veozah, Myrbetriq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $233.96 | 2021-2023 | |
| Pfizer INC. | $211.02 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $208.72 | 2019-2023 | Eliquis |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Ellison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.